Navigation Links
Hovione's TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
Date:9/8/2009

LOURES, Portugal, September 8 /PRNewswire/ -- Hovione is pleased to announce that its TwinCaps(R) inhaler licensees Daiichi Sankyo Co. Ltd. (Tokyo, Japan) and Biota Holdings Ltd (Victoria, Australia) have both announced successful Phase III trials for CS-8958, a new long-acting neuraminidase inhibitor for treatment of influenza (known as a prodrug of laninamivir).

CS-8958, co-owned by Daiichi Sankyo and Biota, is delivered by TwinCaps(R), a patented dry powder inhaler which Hovione specifically designed for the treatment and prevention of influenza infections in both seasonal and pandemics situations. The device was designed to be used across a broad range of patients' inspiratory flow rates and requires a single priming action prior to use.

In the Phase III trials conducted by Daiichi Sankyo, a single inhaled dose of CS-8958 was shown to be as effective as oseltamivir (Tamiflu(R)) administered orally twice daily for 5 days (total of 10 doses). A parallel Phase II/III trial of CS-8958 in paediatric patients also met the primary and secondary endpoints compared to oseltamivir.

CS-8958 is an important new treatment against influenza as current neuraminidase inhibitors for influenza require daily or more frequent dosing, compared to CS-8958 which requires one dose for treatment and possibly once-weekly dosing for prophylaxis). The ability to dose patients on a weekly, or even less frequent, basis offers numerous benefits. Firstly, the volume of product stored in stockpile reserves may be smaller and secondly, a single-dose treatment will offer better patient compliance and convenience.

TwinCaps(R), for which patent applications were filed world-wide in 2006, is an innovative inhaler, delivering a significant dose of drug to the lung, in a simple device comprising only two plastic components. Daiichi Sankyo and Biota have a worldwide exclusive license to use TwinCaps(R) for the tre
'/>"/>

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
2. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
3. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
4. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
5. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
6. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
11. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... /PRNewswire-iReach/ -- Today leading web researchers Change Sciences Group ... web sites for usability, engagement, and conversion. The rankings ... which compares how people experience sites with competitors and ... The top three performers are easier to use, more ... performers have usability problems, lack aspects of design that ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... Quebec , June 18, 2013 Valeant ... TSX: VRX) (the "Company") announced today that VPII Escrow ... the Company, has launched its offer of approximately $3.2 ... "Notes").  The Notes will be due in 2021 and ... The Company intends to use the net proceeds ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... 2011 When consumers are offered a cost-neutral choice ... store or through a mail-order pharmacy, they split their ... study from CVS Caremark (NYSE: CVS ) ... study, published in the January edition of the ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... BMN 701, a novel fusion protein of insulin-like growth factor ... treatment of Pompe disease. "We have a strong ... medical needs and expect to leverage our clinical and regulatory ...
Cached Medicine Technology:CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 2CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions 3BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 2BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease 3
(Date:6/19/2013)... Children had half as many emergency department visits if ... five or more days a week, according to new ... Hospital and Johns Hopkins University. , The new study ... of Pediatrics and will be presented at the ... important step in understanding where primary care practices and ...
(Date:6/19/2013)... are increasingly common on college campuses, but are ... up"? A new study by researchers with The ... published online by the Archives of Sexual ... behaviors associated with sexual hookups, particularly among first-year ... negative emotional and physical health outcomes as a ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...
(Date:6/19/2013)... Alternatives, a revolutionary new treatment facility located ... drugs while allowing them to continue drinking alcohol. Drs. ... believe that abstinence-only approaches force people to wait until ... this approach hurts instead of helping. It is ... need treatment for addiction but only 3 million seek ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
... way to treat castrate resistant cells in prostate cancer ... For more than 60 years the main way ... the hormones that fuel growth of the cancer cells. ... the tumour growth resumes, the disease in incurable. The ...
... , ... ... ... ...
... ... ... ... ...
... ... ... of complex government regulation some of the stand-out questions include:, , ,   ... How are these standards impacted by the convergence of media and conflation of traditional media ...
... ... ... ... ...
... ... ... ... ...
Cached Medicine News:Health News:Effective prostate cancer treatment discovery 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 2Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 3Health News:Verizon Health Care IT Experts to Present at Atlanta Conference on March 2, 3 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 2Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 3Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 4Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 5Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 6Health News:AFL-CIO President Richard Trumka to Discuss TSA Bargaining Rights on 'Inside Government' Radio Show 7Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 2Health News:Alan Chapell, President of Chapell & Associates to Deliver Keynote at the Next AdMonsters US Leadership Forum 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 2Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 3Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 4Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 5Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 6Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 7Health News:VIDEO from Medialink and American Lung Association: Don't Quit on Your Resolution to Quit Smoking! 8Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 2Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 3Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 4Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 5Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 6
... Blood Collection Tubes are used ... blood samples for use with ... chemistry cartridges requiring either 95 ... sample. These tubes are Mylar-wrapped ...
... FEMTO LDV, the first compact, mobile femtosecond ... a versatile, powerful platform for a wide ... basic system addresses the demand of refractive ... is consistent with an efficient LASIK work-flow. ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: